person · Reporting owner
MAZELSKY JONATHAN JAY
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | September 30, 2026 | October 03, 2026 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director · President and CEO | February 26, 2026 | March 02, 2026 |
| INSULET CORPPODD · Entity 3516 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DENTSPLY SIRONA Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock (Directors' Deferred Compensation) DDCSEC Table II · derivative / convertible security | Direct | 23,345.1175 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 3,323.4332 · Balance 23,345.1175 F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2: Comprised of phantom stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director.
F2: Comprised of phantom stock.
IDEXX LABORATORIES INC /DE
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,803.302 |
Ending reported balance
After 2026-02-27 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-02-26 · Exercise / conversion · Acquired 23,326 · Balance 106,932.302 Row 2 · 2026-02-26 · Sale · Disposed 1,281 · Balance 105,651.302 F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2026-02-26 · Sale · Disposed 1,095 · Balance 104,556.302 F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 4 · 2026-02-26 · Sale · Disposed 1,669 · Balance 102,887.302 F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 5 · 2026-02-26 · Sale · Disposed 1,171 · Balance 101,716.302 F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 6 · 2026-02-26 · Sale · Disposed 1,111 · Balance 100,605.302 F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 7 · 2026-02-26 · Sale · Disposed 1,488 · Balance 99,117.302 F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 8 · 2026-02-26 · Sale · Disposed 1,343 · Balance 97,774.302 F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 9 · 2026-02-26 · Sale · Disposed 2,860 · Balance 94,914.302 F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 10 · 2026-02-26 · Sale · Disposed 3,660 · Balance 91,254.302 F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 11 · 2026-02-26 · Sale · Disposed 2,859 · Balance 88,395.302 F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 12 · 2026-02-26 · Sale · Disposed 1,200 · Balance 87,195.302 F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 13 · 2026-02-26 · Sale · Disposed 1,000 · Balance 86,195.302 F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 14 · 2026-02-26 · Sale · Disposed 2,589 · Balance 83,606.302 F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 15 · 2026-02-27 · Exercise / conversion · Acquired 197 · Balance 83,803.302 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $141.60 · Expires 2027-02-13 | Direct | 0 |
Reported balance
After 2026-02-26 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-02-26 · Exercise / conversion · Disposed 23,326 · Balance 0 F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $505.53 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-02-27 · Exercise / conversion · Disposed 197 · Balance 0 F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018.
F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.
INSULET CORP
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,496 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 141 · Balance 1,496 F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2026 Filed Jan 2, 2026 21:30 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 2,637.9487 | $11.37 | $29,993.48 |
DisclosureSEC source: 0000818479-26-000003 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,381.5129 Underlying: Common Stock · 2,637.9487 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:23 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 141 | $130.47 | $18,396.27 |
DisclosureSEC source: 0001145197-26-000184 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,496 F1 · shares: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:07 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 3,323.4332 | $9.03 | $30,010.60 |
DisclosureSEC source: 0000818479-26-000271 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,345.1175 Underlying: Common Stock · 3,323.4332 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:12 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-26-000155 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,355 F1 · shares: Initial equity award in the form of restricted stock units ("RSUs"). RSUs are settled in shares of common stock on a one-for-one basis. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:35 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 2,841.8303 | $10.56 | $30,009.73 |
DisclosureSEC source: 0000818479-26-000234 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,021.6843 Underlying: Common Stock · 2,841.8303 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 21:02 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 10,000 | $10.14 | $101,400.00 |
DisclosureSEC source: 0000818479-26-000210 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,668.534 Read SEC document |
| June 12, 2026 Filed Jun 18, 2026 22:23 UTC Amendment | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | PurchaseCommon Stock | 10,000 | $10.14 | $101,400.00 |
DisclosureSEC source: 0000818479-26-000218 · form4a.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,668.534 F1 · kind: This amendment is being filed to correct the transaction code reported in Table I of the original Form 4 filed on June 15, 2026. The transaction was inadvertently reported using transaction code A. The correct transaction code is P, which reflects that the transaction was an open market purchase. All other information in the original filing remains unchanged. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:33 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 22,822 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-26-000188 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,668.534 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:09 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 2,644.6402 | $11.34 | $29,990.22 |
DisclosureSEC source: 0000818479-26-000119 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,179.854 Underlying: Common Stock · 2,644.6402 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 197 | $0.00 Strike: $505.53 | $0.00 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · derivative · entry 17 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 197 shares Expires 2032-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 197 | $505.53 | $99,589.41 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 15 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,803.302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 23,326 | $0.00 Strike: $141.60 | $0.00 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · derivative · entry 16 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,326 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,589 | $663.04 | $1,716,620.66 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 14 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,606.302 F13 · price: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $662.16 | $662,156.70 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 13 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,195.302 F12 · price: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,200 | $661.10 | $793,317.12 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 12 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,195.302 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,859 | $659.75 | $1,886,223.82 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 11 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,395.302 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,660 | $658.92 | $2,411,634.76 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 10 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,254.302 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,860 | $657.84 | $1,881,433.27 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,914.302 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,343 | $656.85 | $882,142.97 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,774.302 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,488 | $655.85 | $975,904.50 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,117.302 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,111 | $654.63 | $727,293.26 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,605.302 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,171 | $653.68 | $765,454.95 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,716.302 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,669 | $652.49 | $1,089,013.32 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,887.302 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,095 | $651.49 | $713,377.83 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,556.302 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,281 | $650.67 | $833,507.63 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,651.302 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 23,326 | $141.60 | $3,302,961.60 |
DisclosureSEC source: 0000874716-26-000043 · wk-form4_1772488807.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,932.302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,099 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000024 · wk-form4_1771374655.xml · derivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,099 Underlying: Common Stock · 1,099 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 958 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000024 · wk-form4_1771374655.xml · derivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 915 | $629.35 | $575,855.25 |
DisclosureSEC source: 0000874716-26-000024 · wk-form4_1771374655.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,606.302 F2 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,099 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000024 · wk-form4_1771374655.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,521.302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 958 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000024 · wk-form4_1771374655.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,422.302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 21 shares purchased under the Issuer's Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 1,943.302 shares held in the ESPP which has been increased by 0.004 shares due to a rounding calculation of previously issued fractional shares. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 13,407 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000024 · wk-form4_1771374655.xml · derivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,407 Underlying: Common Stock · 13,407 shares Expires not disclosed F3 · derivative.exercise_price: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027. F3 · derivative.exercise_date: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027. F3 · derivative.expiration_date: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:36 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 153.7009 | $12.22 | $1,878.22 |
DisclosureSEC source: 0000818479-26-000035 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,535.2138 Underlying: Common Stock · 153.7009 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:36 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 395.158 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-26-000035 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,846.534 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| October 10, 2025 Filed Oct 15, 2025 20:51 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 123.3618 | $11.98 | $1,477.87 |
DisclosureSEC source: 0000818479-25-000215 · form4.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,743.5642 Underlying: Common Stock · 123.3618 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F3 · shares: Comprised of phantom stock acquired as a result of accrued dividends. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| October 10, 2025 Filed Oct 15, 2025 20:51 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 359.576 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-25-000215 · form4.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,451.376 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:11 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantPhantom Stock (Directors' Deferred Compensation) DDC · Derivative | 2,386.165 | $12.57 | $29,994.09 |
DisclosureSEC source: 0000818479-25-000176 · form4.xml · derivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,620.2024 Underlying: Common Stock · 2,386.165 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F2 · shares: Comprised of phantom stock. F1 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting person's termination of service as a director. Read SEC document |
| August 15, 2025 Filed Sep 4, 2025 22:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 1,051 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000152 · wk-form4_1757024398.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,443.3016 Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionPremium Incentive Stock Option (right-to-buy) · Derivative | 183 | Not disclosed Strike: $598.49 | Not disclosed |
DisclosureSEC source: 0000874716-25-000134 · wk-form4_1755032408.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 183 shares Expires 2031-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option at a 110% premium to the closing price of Issuer common stock on the Nasdaq Global Select Market on February 12, 2021 to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 183 | $598.49 | $109,523.30 |
DisclosureSEC source: 0000874716-25-000134 · wk-form4_1755032408.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,494.3016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 29,260 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · derivative · entry 12 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,260 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · price: Not applicable F12 · derivative.exercise_date: Grant of option to buy 41,260 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 660 | $639.37 | $421,985.39 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 11 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,311.3016 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $639.235 to a high of 639.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 880 | $636.81 | $560,391.30 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 10 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,971.3016 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $636.66 to a high of $637.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,822 | $636.15 | $1,159,068.40 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,851.3016 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $635.66 to a high of $636.53 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,526 | $635.13 | $2,239,457.10 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,673.3016 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $634.66 to a high of $635.64 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,000 | $632.56 | $1,897,689.00 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,199.3016 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $632.41 to a high of $633.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,299 | $631.61 | $4,610,095.84 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,199.3016 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $631.26 to a high of $632.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,056 | $630.59 | $3,818,874.24 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,498.3016 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $630.14 to a high of $630.885 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,397 | $629.82 | $2,139,508.05 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,554.3016 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $629.14 to a high of $630.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 00:38 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,525 | $628.27 | $958,114.80 |
DisclosureSEC source: 0000874716-25-000126 · wk-form4_1754699884.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,951.3016 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $627.72 to a high of $628.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.